Sign up USA
Proactive Investors - Run By Investors For Investors
Markets

Chegg, Molina Healthcare and Kadmon Holdings - AFTER HOURS

Chegg chugged higher while Kadmon put on a spurt but investors gave Molina the cold shoulder
Students
There was a 47% year-on-year increase in the number of Chegg Services subscribers

After-hours’ trading activity was light on news from the market’s heavy hitters on Monday.

Chegg Inc (NYSE:CHGG) chugged higher, rising 2.1% to US$16.71, after hailing 2017 as its “best year yet”.

In the fourth quarter, the learning platform operator reported a 17% increase in revenues from the year before at US$73.5mln.

Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) clocked in at US$21.1mln on the back of a 47% year-on-year increase in the number of Chegg Services subscribers.

Fourth quarter earnings per share of 17 cents were comfortably ahead of the Street’s consensus forecast of four cents.

Molina Healthcare Inc (NYSE:MOH), a provider of Medicaid-related solutions for low income families and individuals, retreated in screen-based trading after reporting a net loss of US$5.49 per share for the fourth quarter.

“The disappointment of contract losses and related goodwill charges, continued restructuring costs, and catch up adjustments to unacceptable Marketplace results are legacies of the past,” claimed Joe Zubretsky, the chief executive officer and president of Molina, as he tried to explain the disappointing earnings.

The company said it expects this year’s net income per share to fall within the range of US$3.00 - US$3.50, or US$3.23 - US$3.73 adjusted to exclude exceptional items.

Molina’s shares were down 4.3% in screen-based trading.

Kadmon Holdings Inc (NYSE:KDMN) shot up 18% to US$5.70 after it announced positive top-line results from a Phase 2 clinical trial evaluating KD025, the company’s Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib.

KD025 was well tolerated and demonstrated clinical benefit.


No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use